StockTipsArenaBeta

BUY Mankind Pharma Limited — Somil Mehta, Sharekhan

BUYMankind Pharma Limited
Mankind Pharma share price target & all analyst calls

bySomil Mehta, SharekhanHorizon: 1–3 months9 Nov 2026via CNBC Awaaz.

Entry₹2,669.5Inferred
Target₹3,000
Total upside +12.38%
Stop loss₹2,500-6.35% risk
CMP₹2,6401d ago
Active-1.11%+13.64%upside left 3 mo left
Follow Somil Mehta for new calls(38% target hit, 98 closed calls)Get alertsWatch MANKIND for new buy/sell callsGet alertsSee 1 other Short-term call on MANKINDSee 83 other Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 15 Nov, 3:41 am IST
17 supporting2 neutral2 opposing
Supports the BUY call (17)

MACD above its signal line — bullish momentum

Technicals · macd·14 Nov · today

Past month's volume 1.4× the prior month's average

Technicals · volume·13 Nov · yesterday

6 advisors have active long-term BUY calls on this stock, with 2 issued in the last 14 days

Advisor consensus · adjacent horizon·11 Nov · 3d ago

1 other SEBI-registered advisor has an active short-term BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·11 Nov · 3d ago

Mankind Pharma shares jump 8% as Q2 profit rises 38% to Rs 716 crore

NewsEt-Markets·27 Oct · 3w ago

(opens in new tab)
Neutral / worth noting (2)

Mankind Pharma Q2 Review: Export Momentum Continues; Systematix Maintains 'Hold'; Check Target Price

NewsNdtv-Profit·27 Oct · 3w ago

(opens in new tab)

Mankind Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.

NSE · Outcome of Board Meeting·26 Oct · 3w ago

(opens in new tab)
Weighs against the BUY call (2)

RSI at 81 — overbought territory

Technicals · rsi·14 Nov · today

1 advisor has an active long-term SELL call on this stock

Advisor consensus · adjacent horizon·31 Jul · 4mo ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Mankind Pharma

All analyst calls on Mankind Pharma

More from Somil Mehta, Sharekhan

Every call and its outcome